IRIS Accounts Production v23.3.1.45 05919542 Board of Directors 1.9.22 31.3.23 31.3.23 0 0 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh059195422022-08-31059195422023-03-31059195422022-09-012023-03-31059195422021-08-31059195422021-09-012022-08-31059195422022-08-3105919542ns10:Originalns15:EnglandWales2022-09-012023-03-3105919542ns14:PoundSterlingns10:Original2022-09-012023-03-3105919542ns10:Originalns10:Director12022-09-012023-03-3105919542ns10:Original2022-09-012023-03-3105919542ns10:Original2023-03-3105919542ns10:Originalns10:PrivateLimitedCompanyLtd2022-09-012023-03-3105919542ns10:Originalns10:SmallEntities2022-09-012023-03-3105919542ns10:Originalns10:AuditExempt-NoAccountantsReport2022-09-012023-03-3105919542ns10:Originalns10:SmallCompaniesRegimeForDirectorsReport2022-09-012023-03-3105919542ns10:SmallCompaniesRegimeForAccountsns10:Original2022-09-012023-03-3105919542ns10:Originalns10:FullAccounts2022-09-012023-03-3105919542ns10:Original2021-09-012022-08-3105919542ns10:Original12022-09-012023-03-3105919542ns10:Originalns10:Director22022-09-012023-03-3105919542ns10:Originalns10:Director32022-09-012023-03-3105919542ns10:Originalns10:Director42022-09-012023-03-3105919542ns10:Originalns10:RegisteredOffice2022-09-012023-03-3105919542ns10:Original2022-08-3105919542ns10:Originalns5:CurrentFinancialInstruments2023-03-3105919542ns10:Originalns5:CurrentFinancialInstruments2022-08-3105919542ns5:ShareCapitalns10:Original2023-03-3105919542ns5:ShareCapitalns10:Original2022-08-3105919542ns10:Originalns5:SharePremium2023-03-3105919542ns10:Originalns5:SharePremium2022-08-3105919542ns10:Originalns5:RetainedEarningsAccumulatedLosses2023-03-3105919542ns10:Originalns5:RetainedEarningsAccumulatedLosses2022-08-3105919542ns10:Originalns5:PlantMachinery2022-09-012023-03-3105919542ns5:IntangibleAssetsOtherThanGoodwillns10:Original2022-08-3105919542ns5:IntangibleAssetsOtherThanGoodwillns10:Original2023-03-3105919542ns5:IntangibleAssetsOtherThanGoodwillns10:Original2022-08-3105919542ns10:Originalns5:PlantMachinery2022-08-3105919542ns10:Originalns5:PlantMachinery2023-03-3105919542ns10:Originalns5:PlantMachinery2022-08-3105919542ns10:Originalns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-03-3105919542ns10:Originalns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-08-3105919542ns10:Originalns5:CurrentFinancialInstruments2022-09-012023-03-31
REGISTERED NUMBER: 05919542 (England and Wales)















Unaudited Financial Statements

for the Period 1 September 2022 to 31 March 2023

for

The London Gastrointestinal Centre Ltd

The London Gastrointestinal Centre Ltd (Registered number: 05919542)






Contents of the Financial Statements
for the Period 1 September 2022 to 31 March 2023




Page

Company Information 1

Statement of Financial Position 2

Notes to the Financial Statements 3


The London Gastrointestinal Centre Ltd

Company Information
for the Period 1 September 2022 to 31 March 2023







DIRECTORS: Dr C Chan
Dr P Prasad
Dr K M Reddy
Dr S Anderson



REGISTERED OFFICE: The Brentano Suite
Solar House
915 High Road
London
N12 8QJ



REGISTERED NUMBER: 05919542 (England and Wales)



ACCOUNTANTS: Pi Accountants
Chartered Certified Accountants
The Brentano Suite
Solar House
915 High Road
London
N12 8QJ



BANKERS: Virgin Money
154-158 Kensington High Street
London
W8 7RL

The London Gastrointestinal Centre Ltd (Registered number: 05919542)

Statement of Financial Position
31 March 2023

31/3/23 31/8/22
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 - -
Tangible assets 5 112 140
Investments 6 26,397 26,397
26,509 26,537

CURRENT ASSETS
Debtors 7 4,193 -
Cash at bank 40,638 32,292
44,831 32,292
CREDITORS
Amounts falling due within one year 8 6,436 18,775
NET CURRENT ASSETS 38,395 13,517
TOTAL ASSETS LESS CURRENT
LIABILITIES

64,904

40,054

PROVISIONS FOR LIABILITIES 21 27
NET ASSETS 64,883 40,027

CAPITAL AND RESERVES
Called up share capital 5 5
Share premium 1,536 1,536
Retained earnings 63,342 38,486
SHAREHOLDERS' FUNDS 64,883 40,027

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 March 2023.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 March 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 11 February 2024 and were signed on its behalf by:





Dr S Anderson - Director


The London Gastrointestinal Centre Ltd (Registered number: 05919542)

Notes to the Financial Statements
for the Period 1 September 2022 to 31 March 2023

1. STATUTORY INFORMATION

The London Gastrointestinal Centre Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 20% on reducing balance

Taxation
Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the period was NIL (2022 - NIL).

4. INTANGIBLE FIXED ASSETS
Other
intangible
assets
£   
COST
At 1 September 2022
and 31 March 2023 24,254
AMORTISATION
At 1 September 2022
and 31 March 2023 24,254
NET BOOK VALUE
At 31 March 2023 -
At 31 August 2022 -

The London Gastrointestinal Centre Ltd (Registered number: 05919542)

Notes to the Financial Statements - continued
for the Period 1 September 2022 to 31 March 2023

4. INTANGIBLE FIXED ASSETS - continued

Intangible asset consist of software and website development to be written off over 3 years.

5. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 September 2022
and 31 March 2023 1,880
DEPRECIATION
At 1 September 2022 1,740
Charge for period 28
At 31 March 2023 1,768
NET BOOK VALUE
At 31 March 2023 112
At 31 August 2022 140

6. FIXED ASSET INVESTMENTS
Interest
in other
participating
interests
£   
COST
At 1 September 2022
and 31 March 2023 26,397
NET BOOK VALUE
At 31 March 2023 26,397
At 31 August 2022 26,397

The company is one of the members in Chelsea Outpatients LLP. The above investment consists of the members capital contribution and associated costs.

7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31/3/23 31/8/22
£    £   
Other debtors 4,193 -

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31/3/23 31/8/22
£    £   
Trade creditors 600 180
Taxation and social security 5,836 6,357
Other creditors - 12,238
6,436 18,775

Included in other creditors are amounts owed to Chelsea Outpatients LLP in which the company has a minority interest.

The London Gastrointestinal Centre Ltd (Registered number: 05919542)

Notes to the Financial Statements - continued
for the Period 1 September 2022 to 31 March 2023

9. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to a director subsisted during the period ended 31 March 2023 and the year ended 31 August 2022:

31/3/23 31/8/22
£    £   
Dr M Banks
Balance outstanding at start of period - (1,688 )
Amounts repaid - 1,688
Amounts written off - -
Amounts waived - -
Balance outstanding at end of period - -

10. RELATED PARTY DISCLOSURES

Share of profits of £34,042 (£40,412- 2022) included the profit and loss account relates to the company's share of profit (loss) in Chelsea Outpatients LLP .